A detailed history of Morgan Stanley transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,342,115 shares of EYPT stock, worth $11.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,342,115
Previous 1,318,897 1.76%
Holding current value
$11.7 Million
Previous $30.5 Million 8.98%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$19.93 - $29.71 $462,734 - $689,806
23,218 Added 1.76%
1,342,115 $27.7 Million
Q4 2023

Feb 13, 2024

BUY
$5.71 - $24.13 $6.75 Million - $28.5 Million
1,182,076 Added 863.96%
1,318,897 $30.5 Million
Q3 2023

Nov 15, 2023

BUY
$7.99 - $15.36 $394,682 - $758,737
49,397 Added 56.5%
136,821 $1.09 Million
Q2 2023

Aug 14, 2023

SELL
$3.03 - $9.0 $5,802 - $17,235
-1,915 Reduced 2.14%
87,424 $760,000
Q1 2023

May 15, 2023

BUY
$2.28 - $5.04 $147,867 - $326,864
64,854 Added 264.87%
89,339 $262,000
Q4 2022

Feb 14, 2023

BUY
$2.37 - $7.2 $34,227 - $103,982
14,442 Added 143.8%
24,485 $85,000
Q3 2022

Nov 14, 2022

SELL
$6.96 - $11.12 $11,609 - $18,548
-1,668 Reduced 14.24%
10,043 $79,000
Q2 2022

Oct 27, 2022

BUY
$7.25 - $12.71 $17,856 - $31,304
2,463 Added 26.63%
11,711 $91,000
Q2 2022

Aug 15, 2022

BUY
$7.25 - $12.71 $17,856 - $31,304
2,463 Added 26.63%
11,711 $91,000
Q1 2022

Oct 27, 2022

SELL
$8.67 - $14.11 $21,354 - $34,752
-2,463 Reduced 21.03%
9,248 $113,000
Q1 2022

May 13, 2022

SELL
$8.67 - $14.11 $92,292 - $150,200
-10,645 Reduced 53.51%
9,248 $113,000
Q4 2021

Feb 14, 2022

BUY
$10.18 - $18.4 $139,598 - $252,319
13,713 Added 221.89%
19,893 $243,000
Q3 2021

Nov 15, 2021

BUY
$7.51 - $11.72 $46,411 - $72,429
6,180 New
6,180 $64,000

Others Institutions Holding EYPT

About EyePoint Pharmaceuticals, Inc.


  • Ticker EYPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,072,200
  • Market Cap $296M
  • Description
  • EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...
More about EYPT
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.